A synthesis was not conducted by the authors since lisinopril therapy was a weakly dominant strategy. The conversion from captopril (in
Most angiotensin converting enzyme inhibitors are prodrugs, requiring hepatic conversion to an active metabolite. Captopril and lisinopril are
Most angiotensin converting enzyme inhibitors are prodrugs, requiring hepatic conversion to an active metabolite. Captopril and lisinopril are
by JW Bransetter 2024This study demonstrates that utilizing lisinopril with a conversion rate of 3 mg of captopril to 1 mg of lisinopril was safe and effective for controlling
This study evaluated safety and efficacy of converting from captopril to lisinopril in patients utilizing a pre-defined conversion of 3 mg captopril to 1 mg lisinopril. This was a single center
Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
Angiotensin-Converting Enzyme Inhibitors - Inhibit the conversion of AngI to AngII Captopril, Lisinopril Losartan, Valsartan, Eprosartan
OBJECTIVE:To provide clinical support that conversion from Captopril to lisinopril at a daily oral dosage ratio of 5:1 maintains comparable therapeutic efficacy, and to estimate retrospectively cost savings because of conversion from Captopril to lisinopril therapy at the study site and with the associated overall drug conversion program instituted by Kaiser Permanente.DESIGN:An open-label
Captopril and lisinopril are the only ACE inhibitors that do not require hepatic conversion to active metabolites and may be preferred in
Comments